Number of patients (%) |
Number of patients (%) |
Number of patients
(%) |
Number of patients (%) |
Number of patients (%) |
Number of
patients (%) |
1580 (86.3%) |
1580 (86.3%) |
251 (13.7%) |
1831 |
Age [years] (±SD) |
Age [years] (±SD) |
Age [years] (±SD) |
Age [years] (±SD) |
Age [years] (±SD) |
Age [years] (±SD) |
42.3 (17.2) |
42.3 (17.2) |
41.5 (18.2) |
42.2 (17.4) |
Gender [Males] n pts (%) |
Gender [Males] n pts (%) |
Gender
[Males] n pts (%) |
Gender [Males] n pts (%) |
Gender
[Males] n pts (%) |
Gender [Males] n pts (%) |
867 (54.9%) |
867 (54.9%) |
132 (52.6%) |
999 (54.6%) |
Smoking |
Smoking |
Smoking |
No |
No |
No |
1087 (68.9%) |
1087 (68.9%) |
172 (68.5%) |
1259
(68.8%) |
|
|
|
Yes |
Yes |
Yes |
365 (23.1%) |
365
(23.1%) |
59 (23.5%) |
424 (23.2%) |
|
|
|
Former smoker |
Former smoker |
Former
smoker |
126 (8.0%) |
126 (8.0%) |
20 (8.0%) |
146
(8.0%) |
Concomitant atopic conditions |
Concomitant atopic conditions |
Concomitant atopic conditions |
Rhinitis |
Rhinitis |
Rhinitis |
741 (46.9%) |
741 (46.9%) |
118 (47.0%) |
859
(46.9%) |
|
|
|
Conjunctivitis |
Conjunctivitis |
Conjunctivitis |
563 (35.7%) |
563 (35.7%) |
77 (30.8%) |
640 (35.0%) |
|
|
|
Asthma |
Asthma |
Asthma |
498 (31.5%) |
498 (31.5%) |
79 (31.5%) |
577 (31.5%) |
Total of treatment course interruptions |
Total of treatment course
interruptions |
Total of treatment course interruptions |
|
|
|
- |
- |
286 |
286 |
Timepoint 1
(lockdown- phase 1)
|
Stopped Therapy
|
By patient decision
|
By patient decision
|
By patient decision
|
-
|
-
|
92/286 (32.2%)
|
92/286 (32.2%)
|
92
|
|
|
By dermatologist |
By dermatologist |
By
dermatologist |
- |
- |
41/286 (14.3%) |
41/286 (14.3%) |
41 |
|
|
By general practitioner |
By general practitioner |
By general practitioner |
- |
- |
12/286 (4.2%) |
12/286
(4.2%) |
12 |
|
|
Unknown |
Unknown |
Unknown |
- |
- |
47/286 (16.4%) |
47/286 (16.4%) |
141 |
|
Reason for stopping therapy |
Any reason |
Any reason |
Any reason |
|
|
192/286 (67.1%) |
192/286 (67.1%) |
|
|
|
Fear of SARS-CoV-2 infection |
Fear of SARS-CoV-2
infection |
Fear of SARS-CoV-2 infection |
- |
- |
62/286
(21.7) |
62/286 (21.7) |
62 |
|
|
SARS-CoV-2 infection |
SARS-CoV-2 infection |
SARS-CoV-2 infection |
- |
- |
6/286 (2.1%) |
6/286 (2.1%) |
6 |
|
|
Contact with SARS-CoV-2+ subject |
Contact with
SARS-CoV-2+ subject |
Contact with SARS-CoV-2+ subject |
- |
- |
7/286 (2.4%) |
7/286 (2.4%) |
7 |
|
|
Comorbidity |
Comorbidity |
Comorbidity |
- |
- |
10/286 (3.5%) |
10/286 (3.5%) |
10 |
|
|
Age > 60 years old |
Age
> 60 years old |
Age > 60 years old |
- |
- |
6/286 (2.1%) |
6/286 (2.1%) |
6 |
|
|
Other (i.e., drug supply, no mobility, etc) |
Other
(i.e., drug supply, no mobility, etc) |
Other (i.e., drug
supply, no mobility, etc) |
- |
- |
101/286 (35.3%) |
101/286 (35.3%) |
101 |
Timepoint 2
(phase 2)
|
Stopped Therapy
|
By patient decision
|
By patient decision
|
By patient decision
|
-
|
-
|
14/286 (4.9%)
|
14/286 (4.9%)
|
14
|
|
|
By dermatologist |
By dermatologist |
By
dermatologist |
- |
- |
22/286 (8.5%) |
22/286 (8.5%) |
22 |
|
|
By general practitioner |
By general practitioner |
By general practitioner |
- |
- |
3/286 (6.0%) |
3/286
(6.0%) |
3 |
|
|
Unknown |
Unknown |
Unknown |
- |
- |
9/286 (1.0%) |
9/286 (1.0%) |
9 |
|
Reason for stopping therapy |
Any reason |
Any reason |
Any reason |
- |
- |
48/286 (16.8% ) |
48/286 (16.8% ) |
48 |
|
|
Fear of SARS-CoV-2 infection |
Fear of SARS-CoV-2
infection |
Fear of SARS-CoV-2 infection |
- |
- |
6/286
(2.1%) |
6/286 (2.1%) |
6 |
|
|
SARS-CoV-2 infection |
SARS-CoV-2 infection |
SARS-CoV-2 infection |
- |
- |
2/286 (0.7%) |
2/286 (0.7%) |
2 |
|
|
Contact with SARS-CoV-2+ subject |
Contact with
SARS-CoV-2+ subject |
Contact with SARS-CoV-2+ subject |
- |
- |
- |
- |
- |
|
|
Comorbidity |
Comorbidity |
Comorbidity |
- |
- |
5/286 (1.7%) |
5/286 (1.7%) |
5 |
|
|
Age > 60 years old |
Age
> 60 years old |
Age > 60 years old |
- |
- |
3/286 (1%) |
3/286 (1%) |
3 |
|
|
Other (i.e., drug supply, no mobility, etc) |
Other
(i.e., drug supply, no mobility, etc) |
Other (i.e., drug
supply, no mobility, etc) |
- |
- |
32/286 (11.2%) |
32/286 (11.2%) |
32 |
Timepoint 3
(phase 3)
|
Stopped Therapy
|
By patient decision
|
By patient decision
|
By patient decision
|
-
|
-
|
8/286 (2.8%)
|
8/286 (2.8%)
|
8
|
|
|
By dermatologist |
By dermatologist |
By
dermatologist |
- |
- |
23/286 (8.0%) |
23/286 (8.0%) |
23 |
|
|
By general practitioner |
By general practitioner |
By general practitioner |
- |
- |
1/286 (2.1%) |
1/286
(2.1%) |
1 |
|
|
Unknown |
Unknown |
Unknown |
- |
- |
14/286 (30.4%) |
14/286 (30.4%) |
14 |
|
Reason for stopping therapy |
Any reason |
Any reason |
Any reason |
- |
- |
46/286 (16.1%) |
46/286 (16.1%) |
46 |
|
|
Fear of SARS-CoV-2 infection |
Fear of SARS-CoV-2
infection |
Fear of SARS-CoV-2 infection |
- |
- |
3/286
(1.0%) |
3/286 (1.0%) |
3 |
|
|
SARS-CoV-2 infection |
SARS-CoV-2 infection |
SARS-CoV-2 infection |
- |
- |
- |
- |
- |
|
|
Contact with SARS-CoV-2+ subject |
Contact with
SARS-CoV-2+ subject |
Contact with SARS-CoV-2+ subject |
- |
- |
- |
- |
- |
|
|
Comorbidity |
Comorbidity |
Comorbidity |
- |
- |
2/286 (0.7%) |
2/286 (0.7%) |
2 |
|
|
Age > 60 years old |
Age
> 60 years old |
Age > 60 years old |
- |
- |
6/286 (2.1%) |
6/286 (2.1%) |
6 |
|
|
Other (i.e., drug supply, no mobility) |
Other
(i.e., drug supply, no mobility) |
Other (i.e., drug supply, no
mobility) |
- |
- |
35/286 (12.2%) |
35/286 (12.2%) |
35 |
Missing data about decision of treatment interruption |
Missing data
about decision of treatment interruption |
Missing data about decision
of treatment interruption |
Missing data about decision of treatment
interruption |
Missing data about decision of treatment interruption |
Missing data about decision of treatment interruption |
Missing data
about decision of treatment interruption |
Missing data about decision
of treatment interruption |
Missing data about decision of treatment
interruption |
70/286 (24.5%) |
Number of patients lost to follow up (%) |
Number of patients lost to
follow up (%) |
Number of patients lost to follow up (%) |
Number of
patients lost to follow up (%) |
Number of patients lost to follow up
(%) |
Number of patients lost to follow up (%) |
Number of patients
lost to follow up (%) |
Number of patients lost to follow up (%) |
Number of patients lost to follow up (%) |
142/1831
(7.7%) |